Analysis of 28 cases of osimertinib related interstitial lung disease based on literature review
AIM To analyze the general patterns and characteristics of osimertinib related interstitial lung disease(ILD).METHODS The case reports of osimertinib related ILD from CNKI,VIP,Wanfang and PubMed database between November 2015 to June 2023 were searched and analyzed.RESULTS A total of 25 case reports were enrolled,involving 28 cases with ILD,14 male and 14 female cases,aged 32 to 86 years old.PD-1 inhibitors were used sequentially in 4 patients before administering osimertinib,21 patients developed ILD in 3 months,25 patients experienced symptom relief after discontinuation reduction medication,and 3 patients died.CONCLUSION ILD should be closely guarded in 3 months of the application of osimertinib,especially these patients who received the sequence treatment of PD-1 inhibitors.The key to improving the prognosis is to stop using osimertinib immediately after ILD.